878 results
Search Results
52. Breast milk concentration of hydroxychloroquine in Chinese lactating women with connective tissue diseases
53. Sex-related differences in safety profiles, pharmacokinetics and tissue distribution of sinomenine hydrochloride in rats
54. Effect of curcumin supplementation on exercise-induced muscle damage: a narrative review
55. Evaluation of vatiquinone drug-drug interaction potential in vitro and in a phase 1 clinical study with tolbutamide, a CYP2C9 substrate, and omeprazole, a CYP2C19 substrate, in healthy subjects
56. Absorption, metabolism and excretion of [14C]-sotorasib in healthy male subjects: characterization of metabolites and a minor albumin-sotorasib conjugate
57. Machines that help machines to help patients: optimising antimicrobial dosing in patients receiving extracorporeal membrane oxygenation and renal replacement therapy using dosing software
58. Population pharmacokinetic model to generate mechanistic insights in bile acid homeostasis and drug-induced cholestasis
59. Cancer targeted contrast studies and photothermal therapy using engineered gold nanoparticles
60. Quantum evaluation and therapeutic activity of (E)-N-(4-methoxyphenyl)-2-(4-(3-oxo-3-phenylprop-1-en-1-yl) phenoxy)acetamide and its modified derivatives against EGFR and VEGFR-2 in the treatment of triple-negative cancer via in silico approach
61. A rapid quantitative method by liquid chromatography–tandem mass spectrometry for the measurement of anthocyanins and their metabolic characteristics in Sprague–Dawley rats
62. Mouse pharmacokinetics and metabolism of the phenylurea thiocarbamate NSC 161128
63. The pharmacokinetics of tacrolimus in peripheral blood mononuclear cells and limited sampling strategy for estimation of exposure in renal transplant recipients
64. Evaluation of a six-probe cocktail (caffeine, tolbutamide, omeprazole, dextromethorphan, midazolam, and digoxin) approach to estimate hepatic drug detoxification capability and dosage requirements after a single oral dosing in healthy Chinese volunteers
65. A prospective study of a simple algorithm to individually dose high-dose methotrexate for children with leukemia at risk for methotrexate toxicities
66. Desmopressin therapy in children and adults: pharmacological considerations and clinical implications
67. Metabolite profiling analysis of plasma, urine, and feces of rats after oral administration of Flos Chrysanthemi Indici preparation through UHPLC-Q-Exactive-MS combined with pharmacokinetic study of markers by UHPLC-QQQ-MS/MS
68. Using maximum plasma concentration (Cmax) to personalize taxane treatment and reduce toxicity
69. A first-in-human phase I study of TAS-117, an allosteric AKT inhibitor, in patients with advanced solid tumors
70. Non-linear IV pharmacokinetics of the ATR inhibitor berzosertib (M6620) in mice
71. Predictors of valproic acid steady-state serum levels in adult and pediatric psychiatric inpatients: a comparative analysis
72. Systematic evaluation of high-throughput PBK modelling strategies for the prediction of intravenous and oral pharmacokinetics in humans
73. Effect of food on the pharmacokinetics and safety profiles of a new PARP inhibitor fuzuloparib capsules in healthy volunteers
74. Pharmacokinetics of nirmatrelvir/ritonavir and the drug-drug interaction with calcineurin inhibitor in renal transplant recipients
75. Pharmacokinetics/pharmacodynamics of ivosidenib in advanced IDH1-mutant cholangiocarcinoma: findings from the phase III ClarIDHy study
76. Medication patterns and dosing guidance in pediatric patients supported with intermittent hemodialysis or continuous kidney replacement therapy
77. Pharmacokinetics and immunogenicity of eftozanermin alfa in subjects with previously-treated solid tumors or hematologic malignancies: results from a phase 1 first-in-human study
78. Safety and pharmacokinetics of imaradenant (AZD4635) in Japanese patients with advanced solid malignancies: a phase I, open-label study
79. Long-term safety and efficacy of cipaglucosidase alfa plus miglustat in individuals living with Pompe disease: an open-label phase I/II study (ATB200-02)
80. Relative bioavailability of fedratinib through various alternative oral administration methods in healthy adults
81. Waiting times between examinations with intravascularly administered contrast media: a review of contrast media pharmacokinetics and updated ESUR Contrast Media Safety Committee guidelines
82. A simplified LC−MS/MS approach for simultaneous quantification and pharmacokinetics of five compounds in rats following oral administration of Gastrodia elata extract
83. Comparative evaluation of 68Ga-labelled TATEs: the impact of chelators on imaging
84. Validation of the HPLC–PDA method for detection of eluxadoline and rifaximin in rat plasma and application in a pharmacokinetic study
85. Evaluation of pharmacogenomics and hepatic nuclear imaging–related covariates by population pharmacokinetic models of irinotecan and its metabolites
86. Clinical response in patients treated with once-monthly paliperidone palmitate: analysis of a therapeutic drug monitoring (TDM) database
87. Principles of dose-setting in toxicology studies: the importance of kinetics for ensuring human safety
88. Preparation of magnetic yolk-shell structured metal-organic framework material and its application in pharmacokinetics study of alkaloids
89. Pharmacokinetics of preoperative intraperitoneal 5-FU in patients with pancreatic ductal adenocarcinoma
90. The Pharmacokinetics and Bio-distribution Studied by Simultaneous Analysis of Curcumin and Paclitaxel in Biosamples
91. An updated review on synthetic cathinones
92. Quantitative HPLC-MS/MS determination of Nuc, the active metabolite of remdesivir, and its pharmacokinetics in rat
93. LC-MS bioanalysis of targeted nasal galantamine bound chitosan nanoparticles in rats’ brain homogenate and plasma
94. Extended retrospective detection of regenerated sarin (GB) in rabbit blood and the IMPA metabolite in urine: a pharmacokinetics study
95. Population pharmacokinetic modelling to quantify the magnitude of drug-drug interactions between amlodipine and antiretroviral drugs
96. Dosimetry and pharmacokinetics of [177Lu]Lu-satoreotide tetraxetan in patients with progressive neuroendocrine tumours
97. Drug-drug interaction perpetrators of oxycodone in patients with cancer: frequency and clinical relevance
98. Challenges of pediatric pharmacotherapy: A narrative review of pharmacokinetics, pharmacodynamics, and pharmacogenetics
99. Clinical pharmacokinetics and pharmacodynamics of ivosidenib in Chinese patients with relapsed or refractory IDH1-mutated acute myeloid leukemia
100. Bidirectional pharmacokinetic drug interactions between olaparib and metformin
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.